GlassScriptPhysician profile
Sanny K Chan
NPI 1043449788
$15,317.89
in general payments reported to CMS, 2019-2025
36 companies · $3,486 in 2025
The $3,486 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $416 · 2021: $2,313 · 2022: $3,372 · 2023: $3,266 · 2024: $2,311 · 2025: $3,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,740 · Honoraria: $175 · Consulting Fee: $86.72 · Education: $60.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,740.36 |
| Honoraria | $175.00 |
| Consulting Fee | $86.72 |
| Education | $60.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,426.84 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Csl Behring | $1,767.83 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,281.47 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,220.01 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,187.19 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Amgen INC. | $879.68 | 2021-2025 | Tezspire |
| Janssen Biotech, INC. | $822.77 | 2022-2025 | Imbruvica, Darzalex, Tecvayli |
| Biocryst US Sales Co., LLC | $810.74 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $713.55 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $674.43 | 2021-2025 | Cuvitru, Takhzyro |
| Octapharma USA, INC. | $455.50 | 2020-2025 | Cutaquig, Panzyga |
| Pfizer INC. | $429.42 | 2021-2025 | |
| Genentech USA, INC. | $360.99 | 2022-2025 | Xolair |
| Aimmune Therapeutics, INC. | $350.00 | 2022-2024 | |
| Optinose US, INC. | $275.45 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $271.95 | 2020-2024 | Ruconest |
| Kaleo, INC. | $212.01 | 2021-2024 | Auvi-Q |
| Ionis Pharmaceuticals, INC. | $128.72 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $127.35 | 2025 | Neffy |
| Abbvie INC. | $125.00 | 2023 | Epkinly |
| Blueprint Medicines Corporation | $120.23 | 2022-2023 | Ayvakit |
| Adma Biomanufacturing LLC | $110.77 | 2020-2025 | |
| Bio Products Laboratory USA, INC. | $79.01 | 2021-2023 | Gammaplex, Coagadex |
| Teva Pharmaceuticals USA, INC. | $76.67 | 2021 | |
| Galderma Laboratories, L.P. | $70.40 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $64.75 | 2025 | Sajazir |
| Alk-Abello, INC | $55.81 | 2022-2023 | Odactra, Ragwitek, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.90 | 2021-2024 | |
| Biocryst Pharmaceuticals, INC. | $28.46 | 2020 | |
| Grifols USA, LLC | $26.23 | 2025 | Xembify |
| Incyte Corporation | $24.98 | 2025 | Opzelura |
| Mylan Specialty L.P. | $21.78 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.77 | 2021 | |
| Hikma Pharmaceuticals USA | $14.69 | 2023 | Ryaltris |
| Sobi, INC | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanny Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.